Regeneron Pharmaceuticals, Inc. (REGN) Tuesday said that the resubmission of Biologics License Application (BLA) for linvoseltamab for the treatment of multiple myeloma has been accepted by the U.S. FDA.
A decision from the regulator is expected on July 10, 2025.
The BLA acceptance follows resolution of third-party fill/finish manufacturing issues identified by the FDA in the previous submission.
For comments and feedback: editorial@rttnews.com